Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Dasiglucagon vs GlucaGen in T1DM
NCT03216226Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Jun 2017
- Primary completion
- Feb 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of dasiglucagon in hypoglycemia, sponsored by Zealand Pharma. Started Jun 2017; status: completed.
02
Drugs
dasiglucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT03216226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216226.